نتائج البحث - "Santiago Mercadal"

1

دورية أكاديمية

Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

المؤلفون: Ricardo Sánchez, Sara Dorado, Yanira Ruíz-Heredia, Alejandro Martín-Muñoz, Juan Manuel Rosa-Rosa, Jordi Ribera, Olga García, Ana Jimenez-Ubieto, Gonzalo Carreño-Tarragona, María Linares, Laura Rufián, Alexandra Juárez, Jaime Carrillo, María José Espino, Mercedes Cáceres, Sara Expósito, Beatriz Cuevas, Raúl Vanegas, Luis Felipe Casado, Anna Torrent, Lurdes Zamora, Santiago Mercadal, Rosa Coll, Marta Cervera, Mireia Morgades, José Ángel Hernández-Rivas, Pilar Bravo, Cristina Serí, Eduardo Anguita, Eva Barragán, Claudia Sargas, Francisca Ferrer-Marín, Jorge Sánchez-Calero, Julián Sevilla, Elena Ruíz, Lucía Villalón, María del Mar Herráez, Rosalía Riaza, Elena Magro, Juan Luis Steegman, Chongwu Wang, Paula de Toledo, Valentín García-Gutiérrez, Rosa Ayala, Josep-Maria Ribera, Santiago Barrio, Joaquín Martínez-López

المصدر: Scientific Reports, Vol 14, Iss 1, Pp 1-2 (2024)

مصطلحات موضوعية: Medicine, Science

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/0e652d8d3361447e85fd3076d25ed2beTest

View record in DOAJ

النص الكامل

2

دورية أكاديمية

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

المصدر: Haematologica, Vol 109, Iss 2 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human immunodeficiency virus (HIV) infection. However, toxicities of these regimens are relevant, especially in older adults and elderly patients. The prospective multicenter BURKIMAB14 trial included four to six blocks of immunochemotherapy according to stage (localized: 1 and 2 non-bulky; advanced: 2 bulky, 3, 4) and age, with dose reduction in patients >55 years old. Dose-intensity of chemotherapy was reduced in patients ≤55 years old after achieving complete metabolic response (CMR). Their outcomes were compared with those of similar patients included in the former BURKIMAB08 trial, in which there was no dose reduction. CMR was attained in 86 of 107 (80%) patients (17/19 in localized stages and 69/88 in advanced stages). Patients from the BURKIMAB14 trial ≤55 years old showed similar overall survival (OS), fewer infections and cytopenias than patients from the BURKIMAB08 trial. Patients >55 years old had a significantly higher treatment- related mortality despite dose reduction of chemotherapy. With a median follow-up of 3.61 years the 4-year OS probability was 73% (range, 63-81%). Age (≤55 vs. >55 years) and stage (localized vs. advanced) had prognostic significance. No significant differences in OS were observed in HIV-positive versus HIV-negative patients. The results of BURKIMAB14 are similar to those of other dose-intensive immunochemotherapy trials. Age >55 years and advanced stage, but not HIV infection, were associated with poor survival. Dose reduction of chemotherapy in young adults in CMR is safe and does not impact outcomes (clinicaltrials gov. Identifier: NCT05049473).

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11200Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/411d49da835d412a8fde1dec8785801fTest

View record in DOAJ

النص الكامل

3

دورية أكاديمية

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL

المصدر: HemaSphere, Vol 7, p e813564b (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/01.HS9.0000971484.81356.4bTest; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/489527695ed3427a885bf9b490d94956Test

View record in DOAJ

النص الكامل

4

دورية أكاديمية

Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

المؤلفون: Ricardo Sánchez, Sara Dorado, Yanira Ruíz-Heredia, Alejandro Martín-Muñoz, Juan Manuel Rosa-Rosa, Jordi Ribera, Olga García, Ana Jimenez-Ubieto, Gonzalo Carreño-Tarragona, María Linares, Laura Rufián, Alexandra Juárez, Jaime Carrillo, María José Espino, Mercedes Cáceres, Sara Expósito, Beatriz Cuevas, Raúl Vanegas, Luis Felipe Casado, Anna Torrent, Lurdes Zamora, Santiago Mercadal, Rosa Coll, Marta Cervera, Mireia Morgades, José Ángel Hernández-Rivas, Pilar Bravo, Cristina Serí, Eduardo Anguita, Eva Barragán, Claudia Sargas, Francisca Ferrer-Marín, Jorge Sánchez-Calero, Julián Sevilla, Elena Ruíz, Lucía Villalón, María del Mar Herráez, Rosalía Riaza, Elena Magro, Juan Luis Steegman, Chongwu Wang, Paula de Toledo, Valentín García-Gutiérrez, Rosa Ayala, Josep-Maria Ribera, Santiago Barrio, Joaquín Martínez-López

المصدر: Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract The screening of the BCR::ABL1 kinase domain (KD) mutation has become a routine analysis in case of warning/failure for chronic myeloid leukemia (CML) and B-cell precursor acute lymphoblastic leukemia (ALL) Philadelphia (Ph)-positive patients. In this study, we present a novel DNA-based next-generation sequencing (NGS) methodology for KD ABL1 mutation detection and monitoring with a 1.0E−4 sensitivity. This approach was validated with a well-stablished RNA-based nested NGS method. The correlation of both techniques for the quantification of ABL1 mutations was high (Pearson r = 0.858, p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/900f483793a442ea9469078a704f59faTest

View record in DOAJ

النص الكامل

5

دورية أكاديمية

Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols

المصدر: HemaSphere, Vol 7, Iss 1, p e810 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: http://journals.lww.com/10.1097/HS9.0000000000000810Test; https://doaj.org/toc/2572-9241Test

الوصول الحر: https://doaj.org/article/499e62ea5fee45b98ab4abebc1ea4606Test

View record in DOAJ

النص الكامل

6

دورية أكاديمية

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

المؤلفون: Celia González-Gil, Mireia Morgades, Thaysa Lopes, Francisco Fuster-Tormo, Jesús García-Chica, Ran Zhao, Pau Montesinos, Anna Torrent, Marina Diaz-Beya, Rosa Coll, Lourdes Hermosín, Santiago Mercadal, José González-Campos, Lurdes Zamora, Teresa Artola, Ferran Vall-Llovera, Mar Tormo, Cristina Gil-Cortés, Pere Barba, Andrés Novo, Jordi Ribera, Teresa Bernal, Paula López de Ugarriza, María-Paz Queipo, Pilar Martínez-Sánchez, Alicia Giménez, Teresa González-Martínez, Antonia Cladera, José Cervera, Rosa Fernández-Martín, María Ángeles Ardaiz, María Jesús Vidal, Ángela Baena, Nuria López-Bigas, Anna Bigas, Jaroslaw Maciejewski, Alberto Orfao, Josep Maria Ribera, Eulalia Genescà

المصدر: Haematologica, Vol 108, Iss 4 (2022)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinicalbiological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5- year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients.

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/10853Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/f665c159564e43d48e5cdc5fc6bc2db5Test

View record in DOAJ

النص الكامل

7

دورية أكاديمية

A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial

المصدر: Cancer Medicine, Vol 9, Iss 7, Pp 2317-2329 (2020)

مصطلحات موضوعية: acute lymphoblastic leukemia, adolescents and young adults, pediatric treatment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Pediatric‐based or ‐inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome‐negative (Ph‐neg) acute lymphoblastic leukemia (ALL). Methods This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15‐30 years with standard‐risk (SR) ALL. Results From 2008 to 2018, 89 patients (38 adolescents [15‐18 years] and 51 young adults [YA, 19‐30 years], median age: 20 [15‐29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty‐two patients were transferred to a high‐risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high‐level of end‐induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%‐47%), with significant differences between adolescents and YA: 13% (4%‐28%) vs 52% (34%‐67%), P = .012. No treatment‐related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5‐year overall survival (OS) was 74% (95%CI: 63%‐85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%‐100%) vs 63% (46%‐80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%‐47%] vs 37% [14%‐61%]; OS: 78% [66%‐90%] vs 61% [31%;91%]). Conclusion A full pediatric trial is feasible and effective for AYA with Ph‐neg, SR‐ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/bf122bd32e5b4ffcb50670c9f459f4a3Test

View record in DOAJ

النص الكامل

8

دورية أكاديمية

The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting

المصدر: Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)

مصطلحات موضوعية: COVID‐19, hematology, leukemia, lymphoma, SARS‐CoV‐2, telemedicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Clinical outcomes of novel coronavirus 2019 disease (COVID‐19) in onco‐hematological patients are unknown. When compared to non‐immunocompromised patients, onco‐hematological patients seem to have higher mortality rates. Aims We describe the characteristics and outcomes of a consecutive cohort of 24 onco‐hematological patients with COVID‐19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. Methods and Results Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID‐19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22‐82) years. Median follow‐up in survivors was 14 (9‐28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1‐10) and 10 (3‐18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D‐dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID‐19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID‐19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (−55%) and chemotherapy sessions (−19%). A significant increase in phone visits was reported (+581%). Conclusion COVID‐19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2573-8348Test

الوصول الحر: https://doaj.org/article/b199fbf0402549ec9e8d7cc78f8eda23Test

View record in DOAJ

النص الكامل